Form 4: Performant Healthcare CFO's RSU Vesting & Tax Sale

Performant Healthcare's CFO, Rohit Ramchandani, acquired shares from RSU vesting and sold a portion for tax liabilities under a Rule 10b5-1 plan.

Summary

• Chief Financial Officer Rohit Ramchandani acquired 54,181 shares of Performant Healthcare Inc. common stock on August 18, 2025, through the vesting of Restricted Stock Units (RSUs).
• Concurrently, 26,972 shares were disposed of at $7.61 per share to cover tax liabilities associated with the RSU vesting.
• The transaction was executed under a Rule 10b5-1 trading plan.
• Following these transactions, the CFO beneficially owns 299,101 shares of common stock.
• The RSUs were granted on May 5, 2023, at no cost, and are designed to vest over a four-year period based on continuous service and specific stock price hurdles.
• The initial stock price for determining hurdles was a 60-day Volume Weighted Average Price (VWAP) of $3.16 per share on the grant date.
• Vesting tranches require stock price increases of +25% ($3.95), +50% ($4.74), +75% ($5.52), and +100% ($6.31) relative to the initial VWAP, with specific timeframes for achieving these hurdles (3-4 years).

Sentiment

Score: 6

Explanation: The filing indicates a standard executive compensation event with a strong incentive structure tied to stock performance, which is generally positive for shareholder alignment. The sale of shares for tax purposes is routine. No negative operational or financial news is present.

Positives

• The CFO's compensation structure directly aligns with shareholder interests through performance-based Restricted Stock Units (RSUs) tied to significant stock price appreciation targets (up to 100% increase).
• The transaction was pre-planned under a Rule 10b5-1 plan, indicating a structured approach to executive compensation and tax management.
• Despite the sale for tax purposes, the CFO retains a substantial beneficial ownership of 299,101 shares, demonstrating continued commitment to the company.

Negatives

• A portion of the vested shares (26,972 shares) was sold to cover tax liabilities, which is a common practice but represents a reduction in direct ownership.
• The vesting of a significant portion of the Restricted Stock Units is contingent upon achieving challenging stock price hurdles, which, if not met, will result in forfeiture of those units.

Risks

• Forfeiture of unvested Restricted Stock Units if specific stock price hurdles are not met within the defined timeframes (3-4 years from grant date).
• Forfeiture of unvested Restricted Stock Units if continuous service conditions are not met.

Future Outlook

The RSU vesting structure provides a clear forward-looking incentive for the Chief Financial Officer, tying a significant portion of their compensation to the achievement of specific stock price appreciation targets ranging from 25% to 100% over the next 3-4 years. This aligns management's financial interests directly with long-term shareholder value creation.

Management Comments

• The Restricted Stock Units were awarded at no cost to the Reporting Person, representing a contingent right to receive one share of PHLT's common stock per unit.
• The vesting of these Restricted Stock Units is contingent upon continuous service and the achievement of specific trading price hurdles for the Company's Common Stock during the relevant vesting periods, with provisions for accelerated vesting under certain conditions.

Industry Context

This SEC Form 4 filing details a routine executive compensation event involving the vesting of performance-based Restricted Stock Units (RSUs) and the subsequent sale of shares for tax purposes. Such equity-based compensation is a standard practice across industries, particularly in healthcare technology and services, to align executive incentives with company performance and shareholder returns. The use of stock price hurdles is a common mechanism to ensure that executive rewards are directly tied to market-driven value creation.

Comparison to Industry Standards

• The use of performance-based Restricted Stock Units (RSUs) with tiered stock price hurdles is a common and effective executive compensation strategy in the healthcare technology and services industry, similar to practices at companies like Change Healthcare or Cotiviti.
• The specific hurdles, requiring stock price increases of 25% to 100% over 3-4 years from an initial VWAP of $3.16, are aggressive and designed to strongly incentivize significant shareholder value creation, comparable to high-growth tech or healthcare firms aiming for substantial market capitalization gains.
• The structure, which includes both time-based (continuous service) and performance-based (stock price) vesting, is a robust model for aligning executive incentives with long-term company performance, often seen in companies seeking to drive strategic growth initiatives.

Related Party Transactions

• The Restricted Stock Unit award to the Chief Financial Officer is a related party transaction, representing a form of executive compensation designed to align management interests with company performance.

Stakeholder Impact

• Shareholders: The performance-based RSU structure aligns the Chief Financial Officer's incentives directly with increasing shareholder value through stock price appreciation.
• Employees: The RSU program is part of the executive compensation framework, potentially setting a precedent for performance-based incentives within the company.

Next Steps

• Continued service by the Chief Financial Officer to meet the continuous service condition for future RSU vesting.
• Achievement of the defined stock price hurdles for the remaining RSU tranches to fully vest the performance-based awards.

Key Dates

Recommendation

This Form 4 filing primarily details a routine executive compensation event involving the vesting of performance-based Restricted Stock Units and a subsequent tax-related share sale. While the incentive structure for the CFO is well-aligned with shareholder interests through aggressive stock price hurdles, this filing alone does not provide new fundamental business or financial information to warrant a change in investment recommendation. It confirms a standard practice for executive equity compensation.

Keywords

Performant Healthcare, PHLT, SEC Form 4, Restricted Stock Units, RSU vesting, executive compensation, stock options, insider trading, Rule 10b5-1 plan, CFO, stock price hurdles